Medford, MA, United States of America

Steffi Koerner

USPTO Granted Patents = 7 


 

Average Co-Inventor Count = 14.6

ph-index = 4

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2013-2015

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):

Title: Steffi Koerner: Innovator in Pharmaceutical Compounds

Introduction

Steffi Koerner, an accomplished inventor based in Medford, Massachusetts, has made significant contributions to the field of pharmaceuticals. With a total of seven patents to her name, she specializes in developing innovative compounds aimed at treating critical health disorders.

Latest Patents

Among her recent groundbreaking inventions are the "Substituted Imidazopyridinyl-Aminopyridine Compounds." This invention not only details the synthesis of these compounds but also explores their application in pharmaceutical compositions for treating cell proliferative disorders, including cancer. Another notable patent by Koerner focuses on "Substituted Imidazopyridinyl Compounds," which also addresses methods of synthesis and their potential in pharmaceutical treatments for similar medical conditions.

Career Highlights

Throughout her career, Steffi Koerner has worked with prominent companies, including Arqule, Inc. and Cytopathfinder, Inc. Her innovative work in these organizations has contributed substantially to advancements in medical research and drug development.

Collaborations

Steffi has collaborated with esteemed colleagues such as Mark Anthony Ashwell and Jean-Marc Lapierre, enhancing her work through shared expertise and innovative ideas. These collaborations have further enriched her scientific contributions and the overall impact of her inventions.

Conclusion

Steffi Koerner's work exemplifies dedication to innovation in the pharmaceutical field. Her patents represent vital steps toward developing effective treatments for complex medical issues. As an inventor, she continues to inspire future generations of researchers and innovators in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…